Increased chemotherapeutic activity of camptothecin in cancer cells by siRNA-induced silencing of WRN helicase

31Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

Abstract

Werner syndrome helicase (WRN) participates in a wide range of DNA activities, including replication, double-strand DNA break repair, telomere and retrovirus long terminal repeat maintenance. Mutations of the WRN gene cause Werner syndrome (WS), an autosomal recessive premature ageing disorder associated with various symptoms related to ageing. In this study, we investigated the siRNA that specifically down-regulates WRN expression. WRN silencing increased markedly the chemotherapeutic activity of camptothecin (CPT) on cancer cells in terms of the extent of efficacy and lowering effective drug dosage, accompanied by suppressing recovery from DNA damage caused by CPT. Here, we propose a potential combination therapy of WRN-siRNA and CPT, looking forward to minimizing the inevitable adverse effects associated with cancer chemotherapy. © 2007 Pharmaceutical Society of Japan.

Cite

CITATION STYLE

APA

Futami, K., Takagi, M., Shimamoto, A., Sugimoto, M., & Furuichi, Y. (2007). Increased chemotherapeutic activity of camptothecin in cancer cells by siRNA-induced silencing of WRN helicase. Biological and Pharmaceutical Bulletin, 30(10), 1958–1961. https://doi.org/10.1248/bpb.30.1958

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free